Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies announced this week that it has signed agreements or received positive medical coverage decisions for its ClonoSeq Assay with several large national and regional health insurers in the US, bringing the total number of covered lives to more than 140 million. The agreements and medical policies expand access to ClonoSeq for minimal residual disease (MRD) testing in patients with lymphoid cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.